Austrian Newborn Screening Program: A perspective of five decades

Journal of Perinatal Medicine

Volumn 42, Issue 2, 2014, Pages 151-158

  Pollak, Arnold ^a   Kasper, David C ^a  

^a UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

Austrian newborn screening program; Highthroughput screening; Inborn errors of metabolism; Rare disorders; Tandem mass spectrometry

Indexed keywords

ADENOSINE DEAMINASE DEFICIENCY; ALPHA 1 ANTITRYPSIN DEFICIENCY; AUSTRIA; CITRULLINEMIA; ELECTROSPRAY; HISTIDINEMIA; HOMOCYSTINURIA; HUMAN; HYPOTHYROIDISM; MAPLE SYRUP URINE DISEASE; METHYLMALONIC ACIDURIA; NEWBORN SCREENING; PHENYLKETONURIA; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY; NEWBORN; TRENDS;

AUSTRIA; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; TANDEM MASS SPECTROMETRY;

EID: 84898639128     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2013-0113     Document Type: Review

References (55)

1. Abrams L, Cronister A, Brown WT, Tassone F, Sherman SL, Finucane B, et al. Newborn, carrier, and early childhood screening recommendations for fragile X. Pediatrics. 2012;130:1126-35.
2. Beck M. Therapy for lysosomal storage disorders. IUBMB Life. 2010;62:33-40.
3. Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenylketonuria. Lancet 1953;265:812-3.
4. Bombard Y, Miller FA, Hayeems RZ, Avard D, Knoppers BM. Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. Eur J Hum Genet. 2010;18:751-60.
5. Buckley RH. The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2012;129:597-604; quiz 605-596.
6. Cavazzana-Calvo M, Andre-Schmutz I, Fischer A. Haematopoietic stem cell transplantation for SCID patients: where do we stand? Br J Haematol. 2013;160:146-52.
7. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem. 2003;49:1797-817.
8. Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem. 1993;39:66-71.
9. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008;122:e39-45.
10. Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009; 124:e1116-25.
11. Dajnoki A, Fekete G, Keutzer J, Orsini JJ, De Jesus VR, Chien YH, et al. Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry. Clin Chim Acta. 2010;411:1428-31.
12. Dajnoki A, Muhl A, Fekete G, Keutzer J, Orsini J, Dejesus V, et al. Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Clin Chem. 2008;54:1624-9.
13. De Jesus VR, Zhang XK, Keutzer J, Bodamer OA, Muhl A, Orsini JJ, et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. Clin Chem. 2009;55:158-64.
14. Dercksen M, Duran M, Ijlst L, Mienie LJ, Reinecke CJ, Ruiter JP, et al. Clinical variability of isovaleric acidemia in a genetically homogeneous population. J Inherit Metab Dis. 2012;35:1021-9.
15. Grunert SC, Wendel U, Lindner M, Leichsenring M, Schwab KO, Vockley J, et al. Clinical and neurocognitive outcome in symptomatic isovaleric acidemia. Orphanet J Rare Dis. 2012;7:9.
16. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics. 2006;117: 1915-21.
17. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43.
18. Haynes CA, De Jesus VR. Improved analysis of C26:0-lysophosphatidylcholine in dried-blood spots via negative ion mode HPLC-ESI-MS/MS for X-linked adrenoleukodystrophy newborn screening. Clin Chim Acta. 2012;413:1217-21.
19. Item CB, Mercimek-Mahmutoglu S, Battini R, Edlinger-Horvat C, Stromberger C, Bodamer O, et al. Characterization of seven novel mutations in seven patients with GAMT deficiency. Hum Mutat. 2004;23:524.
20. Item CB, Stockler-Ipsiroglu S, Stromberger C, Muhl A, Alessandri MG, Bianchi MC, et al. Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. Am J Hum Genet. 2001;69:1127-33.
21. Kasper DC, Ratschmann R, Metz TF, Mechtler TP, Moslinger D, Konstantopoulou V, et al. The national Austrian newborn screening program-eight years experience with mass spectrometry. Past, present, and future goals. Wien Klin Wochenschr. 2010;122:607-13.
22. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med. 2003;348:50-8.
23. Knoll E, Wehle E, Thalhammer O. Psychometry and psychological observations in early treated children with phenylketonuria (PKU) during 12 years (author's transl). Klin Padiatr. 1980;192:599-607.
24. Leung DG, Wagner KR. Therapeutic advances in muscular dystrophy. Ann Neurol. 2013;74:404-11.
25. Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis. 2012;35:603-11.
26. Lyon E, Laver T, Yu P, Jama M, Young K, Zoccoli M, et al. A simple, high-throughput assay for Fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. J Mol Diagn. 2010;12:505-11.
27. McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med. 2011;13:230-54.
28. Mechtler TP, Metz TF, Muller HG, Ostermann K, Ratschmann R, De Jesus VR, et al. Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;908:9-17.
29. Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 2012;379:335-41.
30. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc. 1999;281: 249-54.
31. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71:304-13.
32. Metz TF, Mechtler TP, Orsini JJ, Martin M, Shushan B, Herman JL, et al. Simplified newborn screening protocol for lysosomal storage disorders. Clin Chem. 2011;57:1286-94.
33. Mutter-Kind Pass (Mother-child booklet). Austrian Federal Ministry of Health. http://www.bmg.gv.at/home/Schwerpunkte/Praevention/Eltern-und-Kind/Mutter-Kind-Pass.
34. Orsini JJ, Morrissey MA, Slavin LN, Wojcik M, Biski C, Martin M, et al. Implementation of newborn screening for Krabbe disease: population study and cutoff determination. Clin Biochem. 2009;42:877-84.
35. Raymond GV, Jones RO, Moser AB. Newborn screening for adrenoleukodystrophy: implications for therapy. Mol Diagn Ther. 2007;11:381-4.
36. Ross LF, Waggoner DJ. Parents: critical stakeholders in expanding newborn screening. J Pediatr. 2012;161:385-9.
37. Scheibenreiter S. Obituary-Prof. Dr. Otto Thalhammer. Screening 1995;4:55-6.
38. Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics. 2009; 123:1191-207.
39. Stöckler-Ipsiroglu S, Bodamer O, Möslinger D, Mühl A. Report: Austrian Newborn Screening. 2000.
40. Thalhammer O. Toxoplasmosis investigation of pregnant women and newborn infants (author's transl). Wien Klin Wochenschr. 1975;87:676-81.
41. Thalhammer O. 21 years "Austrian Program for Early Detection of Congenital Metabolic Abnormalities." Did the screening programs also contribute scientific knowledge?. Wien Klin Wochenschr. 1988;100:641-5.
42. Thalhammer O, Getreuer V. Information on the "Vienna test program" for the early detection of phenylketonuria. Wien Klin Wochenschr. 1966;78:440-2.
43. Thalhammer O, Scheibenreiter S, Biedl E. Austrian program for the early detection of inborn errors of metabolism. Wien Klin Wochenschr. 1970;82:1-6.
44. Thalhammer O, Scheibenreiter S, Knoll E, Wehle E, Schon R. 12 years Austrian newborn screening for inborn errors of metabolism. Results with special reference to phenylketonuria, hyperphenylalaninemia and histidinemia (author's transl). Klin Padiatr. 1980;192:589-98.
45. Thalhammer O, Scheibenreiter S, Schon R, Knoll E, Schmierer G. 5 years of the Austrian program for the early detection of inborn errors of metabolism. Activity report. Wien Klin Wochenschr. 1972;84:3-12.
46. Timmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav. 2010;51:408-23.
47. Turgeon CT, Magera MJ, Cuthbert CD, Loken PR, Gavrilov DK, Tortorelli S, et al. Determination of total homocysteine, methylmalonic acid, and 2-methylcitric acid in dried blood spots by tandem mass spectrometry. Clin Chem. 2010;56:1686-95.
48. Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003;111:1399-406.
49. Sommerburg O, Lindner M, Muckenthaler M, Kohlmueller D, Leible S, Feneberg R, et al. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis. 2010;33:S263-71.
50. Stockler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet. 1996;348:789-90.
51. Stromberger C, Bodamer OA, Stockler-Ipsiroglu S. Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. J Inherit Metab Dis. 2003;26:299-308.
52. Vernooij-van Langen AM, Loeber JG, Elvers B, Triepels RH, Gille JJ, Van der Ploeg CP, et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax. 2012;67:289-95.
53. Weissel M, Fritzsche H, Hofer R, Frisch H, Thalhammer O. Screening for congenital hypothyroidism. Lancet. 1976;2:1245.
54. Widhalm K, Virmani K. Long-term follow-up of 58 patients with histidinemia treated with a histidine-restricted diet: no effect of therapy. Pediatrics 1994;94:861-6.
55. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003;348:2304-12.